COIOSDeep risk insights through multi-disciplinary research across the globe
a man riding a skateboard down a set of stairs
Item new Peer-reviewed Added

Carbapenemase-producing Enterobacterales doubled every 2.4 years in French hospitals

In French hospitals between 2019 and 2024, carbapenemase-producing Enterobacterales rose 32.8% a year and doubled every 2.4 years, while the far commoner extended-spectrum beta-lactamase producers remained stable.

A retrospective modelling study used the French SPARES surveillance programme to compare the two resistance types in hospitals between 2019 and 2024. Incidence of extended-spectrum beta-lactamase producers was stable at 0.53 to 0.70 cases per 1,000 patient-days. Carbapenemase producers rose 32.8% a year, from a much lower base of 0.010 to 0.037 cases per 1,000 patient-days.

Why it is interesting: On unchanged dynamics, the rarer mechanism is modelled to reach today's level of the commoner one by 2033.

Source
Journal of Hospital Infection, 22 September 2026
Paper
Divergent epidemic trajectories of ESBL-producing and carbapenemase-producing Enterobacterales in French hospitals: a nationwide modelling study
Authors
Davido B, Rouillard L, Leroux P, Durand M, Saleh-Mghir A
DOI
10.1016/j.jhin.2026.09.022
Type
Peer-reviewed article
Design
Retrospective log-linear modelling of national hospital surveillance (SPARES), France, 2019-2024
Verdict
New finding
Driver
Infection and pandemics
Free full text
Free to read at the publisher
Abstract — the authors' own words, CC BY

Objectives

Carbapenemase-producing Enterobacterales (CPE) have emerged as a major public health concern despite remaining less frequent than extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E). Conventional surveillance primarily reports annual incidence but provides limited information on epidemic velocity. We compared the epidemic trajectories of ESBL-E and CPE in French hospitals using nationwide surveillance data. Methods

We conducted a nationwide retrospective modelling study using data from the French SPARES surveillance programme (2019-2024). Annual incidence densities (cases per 1,000 patient-days) were analysed using comparative log-linear regression to estimate annual percent change (APC), doubling time and the projected year at which CPE incidence would reach the observed 2024 ESBL-E incidence under unchanged epidemic dynamics. Species distribution and carbapenemase families were also described. Results

Between 2019 and 2024, ESBL-E incidence remained substantially higher than CPE incidence (0.53-0.70 vs 0.010-0.037 cases per 1,000 patient-days). ESBL-E incidence remained stable over time (APC, 3.1%; P for temporal trend = 0.29), whereas CPE incidence increased significantly faster (APC, 32.8%; P for interaction Conclusions

Although CPE incidence remains markedly lower than ESBL-E incidence, its epidemic trajectory is substantially steeper. Comparative modelling of epidemic trajectories complements conventional surveillance and may help anticipate future antimicrobial resistance burden while opportunities for infection prevention and antimicrobial stewardship remain.

Other drivers in Behavioural science